Aikenuo focuses on the research on the "cell death-inflammation" circuit, a common mechanism of many major diseases, and is committed to self-developed drugs for the treatment of inflammator......
Investors 1
| Date | Name | Website |
| 06.09.2022 | HONGTAI Ap... | apluscap.c... |
Mentions in press and media 3
| Date | Title | Description |
| 19.05.2026 | Accro Bioscience Raises $50M to Advance Ulcerative Colitis Drug Pipeline | Series C Funding Strengthens Accro Bioscience Clinical Pipeline Accro Bioscience just raised $50 million in Series C funding to speed up its clinical development programs. They’re working on treatments for immune-mediated and inflammatory d... |
| 25.05.2023 | TYK2/JAK1 Inhibitor AC-201 of Accropeutics Bioscience gained Human Research Ethics Committees (HREC) permission for Phase I | SUZHOU, China, May 25, 2023 /PRNewswire/ -- Accropeutics Bioscience announced that its oral small molecule TYK2/JAK1 inhibitor AC-201 has been approved by the Australian Human Research Ethics Committee (HREC) to launch a clinical phase I tr... |
| - | Accro Bioscience | “Accro Bioscience(Suzhou)Limited” |